News | February 16, 2022
Moderna announces expansion in key Asian markets
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Subscribe To Our Newsletter & Stay Updated
